Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central anxious system, conolidine modulates alternate molecular targets. A Science Advances review found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://franko985prs7.wikilentillas.com/user